Биостатистика, фармакокинетика и клинические исследования.

Домашняя страница
- О сайте
Материалы
- Быстрые команды R Project
- Ссылки
Инструменты
- Рандомизационный список
Блог
Контакты
Профиль
- Войти
- Зарегистрироваться

Long WS Wide: или про то, как выполнить анализ разницы изменений между группами
Частые вопросы: Регистрация и экспертиза по правилам ЕАЭС
Главные ошибки при формировании базы данных в MS Excel
Тест ClinicalTrialUtilities и ReplicateBE на Raspberry Pi 4
Julia:ReplicateBE – release 0.2.0

Галерея

Meeting of the Oncologic Drugs Advisory Committee - 05/20/2025
Source: FDA - What's New: Drugs RSS Feed Published on 2025-05-09 By FDA
Fiscal Year 2025 Generic Drug Science and Research Initiatives Public Workshop - 06/03/2025
Source: FDA - What's New: Drugs RSS Feed Published on 2025-05-08 By FDA
Tianeptine
Source: FDA - What's New: Drugs RSS Feed Published on 2025-05-08 By FDA
Human medicines European public assessment report (EPAR): Carvykti, ciltacabtagene autoleucel, Date of authorisation: 25/05/2022, Revision: 10, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-05-08
Oncology (Cancer)/Hematologic Malignancies Approval Notifications
Source: FDA - What's New: Drugs RSS Feed Published on 2025-05-08 By FDA
Counterfeit Medicine
Source: FDA - What's New: Drugs RSS Feed Published on 2025-05-08 By FDA
FDA grants accelerated approval to the combination of avutometinib and defactinib for KRAS-mutated recurrent low-grade serous ovarian cancer
Source: FDA - What's New: Drugs RSS Feed Published on 2025-05-08 By FDA
Human medicines European public assessment report (EPAR): Tuzulby, methylphenidate hydrochloride, Date of authorisation: 28/02/2025, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-05-08
Human medicines European public assessment report (EPAR): Neupro, rotigotine, Date of authorisation: 15/02/2006, Revision: 36, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-05-08
European Medicines Agency Write PMS API implementation Guide (zip)
Source: EMA - Regulatory and procedural guidelines (human and veterinary) Published on 2025-05-08
Patent Certifications and Suitability Petitions
Source: FDA - What's New: Drugs RSS Feed Published on 2025-05-08 By FDA
Human medicines European public assessment report (EPAR): Givlaari, givosiran, Date of authorisation: 02/03/2020, Revision: 7, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-05-08
Human medicines European public assessment report (EPAR): Vimpat, lacosamide, Date of authorisation: 29/08/2008, Revision: 55, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-05-08
Concept paper on the revision of Part IV guidelines on good manufacturing practice specific to advanced therapy medicinal products
Source: EMA - Scientific guidelines (human and veterinary) Published on 2025-05-08
Human medicines European public assessment report (EPAR): Tacforius, tacrolimus, Date of authorisation: 08/12/2017, Revision: 10, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-05-08

Предыдущие записи

Тема: Scaffold от Danny Cooper.